Dante Carrillo
Several diet pills have been associated with an increased risk of developing pulmonary hypertension. In the late 1960s and early 1970s, an epidemic of pulmonary hypertension cases in Switzerland, Germany, and Austria was linked to the use of aminorex, an amphetamine-based weight-loss drug. Since then, other diet pills such as fenfluramine, dexfenfluramine, and phentermine have also been associated with pulmonary hypertension. These drugs work by increasing serotonin levels, which can cause changes in the blood vessels in the lungs, leading to lung and heart damage. Additionally, methamphetamine (METH) use has been linked to the development of pulmonary arterial hypertension (PAH), particularly when injected intravenously. While the exact mechanisms are still being studied, the serotonin hypothesis suggests that increased serotonin levels play a significant role in diet pill-associated PAH.
| Characteristics | Values |
|---|---|
| Diet pills | Aminorex, fenfluramine, dexfenfluramine, phentermine |
| Type of drugs | Appetite-suppressant, anorexigens, serotonin precursor |
| Side effects | Pulmonary arterial hypertension (PAH), valvular heart disease, lung and heart damage, plexogenic pulmonary hypertension |
| Other drugs with similar side effects | Amphetamine, methamphetamine, L-tryptophan |
| Risk factors | Family history of pulmonary hypertension, living at high altitudes, smoking, underlying heart or lung problems, blood clots in pulmonary arteries, connective tissue disease, Down syndrome, Gaucher disease, heart disease, liver disease, lung disease |
Explore related products
What You'll Learn
- Aminorex, a weight-loss and mood disorder drug, was linked to a small epidemic of pulmonary hypertension in Switzerland, Germany and Austria in the 1960s and 1970s
- Fenfluramine, an anorectic drug, is known to cause pulmonary hypertension
- Dexfenfluramine, a weight-loss drug, increases the risk of developing pulmonary arterial hypertension
- Phentermine, an appetite-suppressant, has been linked to pulmonary hypertension
- Methamphetamine (METH), a highly addictive drug, has been linked to the development of pulmonary arterial hypertension
Aminorex, a weight-loss and mood disorder drug, was linked to a small epidemic of pulmonary hypertension in Switzerland, Germany and Austria in the 1960s and 1970s
Aminorex, an anorectic drug, was linked to a small epidemic of pulmonary hypertension in Switzerland, Germany, and Austria in the 1960s and early 1970s. Aminorex, also known as aminorex fumarate (2-amino-5-phenyl-2-oxazoline), is an amphetamine-like, appetite-suppressant or anorexigenic drug. It was marketed as a weight-loss and mood disorder drug.
In 1965, an unusually large number of cases of pulmonary arterial hypertension (PAH) were reported in these countries. Researchers found a link between this condition and exposure to aminorex. The epidemic of pulmonary hypertension caused by aminorex peaked in 1968-69 and disappeared after 1972. The mechanism leading to pulmonary hypertension was chronic precapillary vascular obstruction due to plexogenic pulmonary arteriopathy. This is the usual and most distinctive anatomical finding in primary pulmonary hypertension.
The risk of pulmonary hypertension after treatment with aminorex was estimated to be 2 in 1000, which was 20 times the risk in the general population. The latent period between drug therapy and the development of the disease may have been related to the dose, but the dose was sometimes small and bore little relation to the degree of elevation in pressure. In one study of 32 patients in Switzerland, 23 took aminorex for three months or longer, and the disease developed in 18 patients during treatment. The pulmonary hypertension caused by aminorex was sometimes reversible. However, 10 years after the epidemic, half of the patients had died, usually of right heart failure.
Aminorex was sold in Europe from 1965 to 1968 and was then withdrawn from the market. The epidemic of pulmonary hypertension had subsided by 1972. The situation in Europe led to a ban on the amphetamine-based drug. However, clinicians continued to see new cases, which prompted the first Pulmonary Hypertension World Symposium in 1973.
Maple Syrup Diet: A Beginner's Guide to Getting Started
You may want to see also
Explore related products
Fenfluramine, an anorectic drug, is known to cause pulmonary hypertension
Fenfluramine is an anorectic drug that has been strongly associated with the development of pulmonary arterial hypertension (PAH). PAH is high blood pressure in the pulmonary arteries, which can be caused by underlying diseases or certain drugs. In the 1960s, an epidemic of PAH occurred in Europe, which was linked to the use of the amphetamine-like, appetite-suppressant drug aminorex fumarate. Since then, other appetite suppressants, including fenfluramine and its d-isomer dexfenfluramine, have also been associated with the development of PAH.
The serotonin hypothesis of PAH was first proposed in the 1990s, suggesting that anorexigens increase free serotonin levels, which can lead to pulmonary artery vasoconstriction and pulmonary artery smooth muscle cell proliferation. Fenfluramine, in particular, has been found to increase plasma serotonin levels, which can cause changes in the blood vessels in the lungs, leading to lung and heart damage. The risk of PAH after treatment with fenfluramine is estimated to be low, but it is still significantly higher than the risk in the general population.
Several studies have provided evidence of the link between fenfluramine and PAH. In one case, a patient developed PAH after taking fenfluramine and the condition regressed when the drug was discontinued, only to recur when the patient took fenfluramine again. Another study found that in rats, fenfluramine caused a dose-dependent increase in pulmonary arterial pressure. Furthermore, the International Primary Pulmonary Hypertension Study showed that there is at least an eightfold increase in the risk of developing PAH in patients who have taken dexfenfluramine for more than three months.
The mechanism by which fenfluramine causes PAH is not yet fully understood. It has been suggested that fenfluramine inhibits potassium current in pulmonary vascular smooth muscle cells, leading to pulmonary vasoconstriction. However, more research is needed to confirm this hypothesis. While the use of fenfluramine as a weight-loss drug has been controversial due to its association with PAH, it is important to note that the development of PAH may also be influenced by genetic susceptibility and other factors.
In summary, fenfluramine is an anorectic drug that has been strongly associated with the development of PAH through its effects on serotonin levels and pulmonary vasoconstriction. While the exact mechanism of action is not fully elucidated, the evidence suggests that fenfluramine increases the risk of PAH, particularly with long-term use. As such, it is important for clinicians to carefully consider the risks and benefits of prescribing fenfluramine for weight loss and to closely monitor patients for any signs or symptoms of PAH.
Dukan Diet: Is It Safe and Sustainable?
You may want to see also
Explore related products
Dexfenfluramine, a weight-loss drug, increases the risk of developing pulmonary arterial hypertension
Dexfenfluramine is a weight-loss drug that has been linked to an increased risk of developing pulmonary arterial hypertension (PAH). PAH is a condition characterised by high blood pressure in the pulmonary arteries, which can lead to serious health complications and even death. The link between dexfenfluramine and PAH was first identified in a cluster of cases in Switzerland, Germany, and Austria in 1965, where researchers found a connection between the use of a similar weight-loss drug called Aminorex and the development of PAH.
Dexfenfluramine, along with other drugs in its class, is known as an anorexigen or appetite suppressant. These drugs work by increasing serotonin levels in the body, which can lead to changes in the blood vessels in the lungs and subsequent lung and heart damage. This mechanism is known as the serotonin hypothesis of PAH, which suggests that increased serotonin levels cause the activation of serotonin receptors, leading to pulmonary artery vasoconstriction and pulmonary artery smooth muscle cell proliferation.
The International Primary Pulmonary Hypertension Study in 1995 cited dexfenfluramine as a risk factor for PAH. The study found that half of the 62 patients with PAH had been taking a "fenfluramine" type drug for at least three months, with some using dexfenfluramine alone and others in combination with phentermine (known as Fen-Phen). This study prompted the ban of Fen-Phen products in Europe in 1997, followed by a ban in the United States two years later.
The association between dexfenfluramine and PAH highlights the potential risks associated with weight-loss medications. While obesity is a significant health concern, the use of drugs like dexfenfluramine underscores the importance of understanding the potential side effects and long-term consequences of such treatments. It is crucial for individuals considering weight-loss drugs to consult with healthcare professionals and be aware of the risks involved.
Furthermore, the case of dexfenfluramine demonstrates the ongoing need for vigilance in monitoring and regulating drugs that may impact the development of PAH. As Dr. de Jesus Perez noted, it is likely that additional drugs, even some approved by regulatory agencies, may be identified as risk factors for PAH in the future. Continuous research, collaboration between medical organisations, and patient education are essential to minimising the risk of drug-induced PAH and improving patient outcomes.
How Ancient Peoples Ate: Dietary Supplementation Explained
You may want to see also
Explore related products
Phentermine, an appetite-suppressant, has been linked to pulmonary hypertension
Obesity is a serious health crisis with strong connections to mortality from chronic diseases. Appetite suppressants, known as anorexigens, have been developed and prescribed to patients for many years to combat this. Phentermine is one such drug. It stimulates the secretion of noradrenalin in the central nervous system and suppresses appetite by regulating β-adrenergic receptors.
Phentermine has been considered a relatively safe drug to treat obesity. However, in 2010, a publication on adverse reactions to central nervous system stimulants and drugs that suppress appetite mentioned phentermine as a possible cause of pulmonary hypertension. This was the first case suggesting a connection between phentermine as a single medication and pulmonary hypertension.
Phentermine and fenfluramine have similar structures, and both compounds have often been prescribed concurrently as an appetite suppressant. In the 1980s, their concurrent usage was reported to have a synergistic effect on dopamine and serotonin release in the rat brain, and Fen-Phen treatment became the mainstay of anorexin treatment. However, this combination treatment was later suggested to have strong ties with pulmonary arterial hypertension (PAH) and valvular heart disease.
In 1995, The International Primary Pulmonary Hypertension Study cited the weight-loss drugs fenfluramine-phentermine (Fen-Phen) and dexfenfluramine (Redux) as increasing an individual’s risk for the development of PAH. These drugs work by increasing serotonin levels in the body, which, in certain individuals, can cause changes in the blood vessels in the lungs, leading to lung and heart damage.
While there have been very few cases and no controlled studies suggesting a connection between PPH and the use of other appetite suppressants such as phentermine, a concrete evaluation on the safety of phentermine single treatment is still unavailable.
Crush's Orange Diet: A Refreshing Twist?
You may want to see also
Explore related products
Methamphetamine (METH), a highly addictive drug, has been linked to the development of pulmonary arterial hypertension
Pulmonary hypertension is high blood pressure in the pulmonary arteries, which can be caused by underlying heart or lung problems. The use of diet medications and recreational drugs has been linked to an increased risk of developing pulmonary hypertension.
Methamphetamine (METH) is a highly addictive drug that stimulates the nervous system. It can be inhaled, smoked, snorted, ingested orally, or injected. METH has been associated with negative effects on the kidneys, heart, and liver.
METH has also been linked to the development of pulmonary arterial hypertension (PAH). PAH causes the pulmonary arteries to become narrow, thick, or stiff, reducing blood flow and increasing pressure in the pulmonary arteries. The lungs are thought to be primarily affected when METH is injected intravenously.
The first suggestion of a link between METH use and pulmonary hypertension was in 1993, when a case report indicated that a young man's pulmonary hypertension may have been caused by prior methamphetamine use. Since then, studies have found that patients with idiopathic pulmonary arterial hypertension (iPAH) had significantly higher rates of METH use compared to patients with other types of pulmonary hypertension.
METH-associated pulmonary arterial hypertension (Meth-APAH) patients have been found to have worse outcomes and a lower five-year survival rate compared to patients with iPAH. Despite therapy, the five-year survival rate for Meth-APAH patients is significantly lower than for IPAH patients. This may be due to a reluctance by clinical teams to use intravenous prostacyclin analogs in Meth-APAH patients due to concerns about appropriate central line and skin site care.
Healthy Eating: Balanced Diet Basics
You may want to see also
Frequently asked questions
Aminorex, fenfluramine, dexfenfluramine, and phentermine have all been linked to pulmonary hypertension.
These drugs increase serotonin levels in the body, which can cause changes in the blood vessels in the lungs, leading to lung and heart damage.
Symptoms of pulmonary hypertension include shortness of breath, fatigue, chest pain, and swelling in the legs and ankles.
